An2 Therapeutics Inc (ANTX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ANTX Annual Balance Sheets →
By examining balance sheet figures across successive periods, users can identify shifts in An2 Therapeutics Inc's financial structure and capital allocation.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent44.32
Available-for-sale Securities, Debt Securities, Current MA34.07
Cash & Short-term Investments78.00
Prepaid Expense And Other Assets Current1.60
Total Current Assets79.99
Long-term investments1.47
Total Assets81.68
Liabilities
Accounts Payable, Current AC1.97
Accrued Liabilities, Current1.75
Other Liabilities, Current1.87
Total Current Liabilities5.59
Total Long-term Debt0.00
Other liabilities, Noncurrent0.17
Total Liabilities5.76
Stockholders' Equity
Additional Paid In Capital Common Stock335.11
Retained Earnings / Accumulated Deficit-259.16
Accumulated Other Comprehensive Income-0.02
Other Equity-0.02
Common Stockholder's Equity75.92
Total Stockholder's Equity75.92
Liabilities & Stockholder's Equity81.68
4 historic quarters locked

Sign in to unlock the full An2 Therapeutics Inc balance sheet history.

About An2 Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-344569

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.